Global Etanercept Market Size To Reach USD 20.8 Billion By 2028

26-Apr-2022 | Facts and Factors

According to the Facts & Factors report, the global etanercept market was worth about 15.5 (USD billion) in 2021 and is predicted to grow to around 20.8 (USD billion) by 2028, with a compound annual growth rate (CAGR) of around 3.3%.

Etanercept is a biopharmaceutical anti-Tumor Necrosis Factor (TNF) agent used to treat autoimmune diseases like spondylitis and arthritis. TNF overproduction in the body causes pain, inflammation, and bone & joint damage. Etanercept inhibits TNF action and thus reduces inflammation. It's used to treat rheumatoid arthritis, juvenile rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.

Browse the full “Etanercept Market By Application (Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Others), By Distribution Network (Online and Offline), and By Region-Global and Regional Industry Trends, Competitive Intelligence, Analysis of Data, Statistical Data, and Forecast 2022-2028" report at https://www.fnfresearch.com/etanercept-market

During the forecast period, the global etanercept market is expected to grow at a rapid pace. This is due to an increase in the prevalence of lifestyle disorders, obesity, accidents, and spondylitis. When compared to certain other therapeutic proteins, Enbrel has seen a significant increase in demand. It is used to treat auto-immune diseases like psoriasis, juvenile rheumatoid arthritis, and plaque. The higher incidence of these diseases is estimated to propel the etanercept market. Furthermore, technological advancements and R & D activities may introduce new opportunities in the global market. However, rising overall treatment costs, the absence of reimbursement policies in developing nations, and treatment side effects are expected to restrain the global market.

The global etanercept market is segregated on the basis of application, distribution network, and region. By application, the market is divided into juvenile idiopathic arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and others. In the year 2021, rheumatoid arthritis held a commanding market share. It is due to the high prevalence of osteoarthritis in different regions around the world. By distribution network, the market is divided into online and offline. In 2021, the offline segment held a commanding market share. It is due to reimbursement policies and the increasing adoption of AI as a supplement to a simple purchase.

North America's market is expected to expand rapidly in the coming years. The region's dominance in the global etanercept market is due to favorable reimbursement scenarios, acceptance of advanced techniques, and a technically sophisticated health care system. Etanercept's other major markets are Europe and the Asia Pacific. The presence of key players, increased investments in R&D activities by major pharma players, and collaborative partnerships between pharma & biotech companies and research institutes drive the etanercept market in these regions.

Report Scope

Some of the main competitors dominating the global etanercept market are GlaxoSmithKline, Novartis, Takeda, Clover Biopharmaceuticals, Johnson & Johnson, Roche, Celltrion, Pfizer, Cipla, and Samsung Bioepis.

Recent Development

• December 2019: Clover Biopharma has begun Phase III studies in China for the Etanercept Biosimilar Candidate SCB-808. The first patient was given an injection of the biosimilar being developed in the preloaded syringe composition for the treatment of rheumatic diseases such as ankylosing spondylitis and rheumatoid arthritis, according to the company. The purpose of this study is to compare the efficacy, safety, and pharmacokinetics of SCB-808 and the originator drug Enbrel® in patients with ankylosing spondylitis after subcutaneous administration. 
• November 2019: Samsung Bioepis and Biogen have announced a major commercialization agreement for two biosimilar applicants. The agreement gives Biogen the option to renew the commercialization term for Samsung Bioepis' three anti-TNF biosimilars – BENEPALI (etanercept), IMRALDI (adalimumab), and FLIXAB (infliximab) – in Europe for an additional five years, bringing the original ten-year agreement to a total of fifteen years. In Germany, France, Spain, Italy, and the United Kingdom, BENEPALI is the most commonly prescribed etanercept (UK). In Europe, IMRALDI is the leading adalimumab biosimilar. The agreement also gives Biogen the option of getting commercialization rights to BENEPALITM, FLIXABITM, and IMRALDITM in China in exchange for market royalties.

The global etanercept market is segmented as follows:

By Application

• Juvenile Idiopathic Arthritis
• Rheumatoid Arthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Others

By Distribution Network

• Online
• Offline

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Reunion
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:
Facts & Factors
A 2108, Sargam,
Nanded City,
Sinhagad Road,
Pune 411041, India
USA: +1-347-989-3985
Email: [email protected]
Web: https://www.fnfresearch.com